<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>643</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15356141</PubmedId>
            <Abstract>The cytotoxic T cell response to pathogens is usually directed against a few immunodominant epitopes, while other potential epitopes are either subdominant or not used at all. In C57BL/6 mice, the acute cytotoxic T cell response against lymphocytic choriomeningitis virus is directed against immunodominant epitopes derived from the glycoprotein (gp33-41) and the nucleoprotein (NP396-404), while the gp276-286 epitope remains subdominant. Despite extensive investigations, the reason for this hierarchy between epitopes is not clear. In this study, we show that the treatment of cells with IFN-gamma enhanced the presentation of gp33-41, whereas presentation of the gp276-286 epitope from the same glycoprotein was markedly reduced. Because proteasomes are crucially involved in epitope generation and because IFN-gamma treatment in vitro and lymphocytic choriomeningitis virus infection in vivo lead to a gradual replacement of constitutive proteasomes by immunoproteasomes, we investigated the role of proteasome composition on epitope hierarchy. Overexpression of the active site subunits of immunoproteasomes LMP2, LMP7, and MECL-1 as well as overexpression of LMP2 alone suppressed the presentation of the gp276-286 epitope. The ability to generate gp276-286-specific CTLs was enhanced in LMP2- and LMP7-deficient mice, and macrophages from these mice showed an elevated presentation of this epitope. In vitro digests demonstrated that fragmentation by immunoproteasomes, but not constitutive proteasomes led to a preferential destruction of the gp276 epitope. Taken together, we show that LMP2 and LMP7 can at least in part determine subdominance and shape the epitope hierarchy of CTL responses in vivo.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>3925-34</ArticlePages>
            <ArticleTitle>Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Basler</LastName>
                    <ForeName>Michael</ForeName>
                </Author>
                <Author>
                    <LastName>Youhnovski</LastName>
                    <ForeName>Nikolay</ForeName>
                </Author>
                <Author>
                    <LastName>Van Den Broek</LastName>
                    <ForeName>Maries</ForeName>
                </Author>
                <Author>
                    <LastName>Przybylski</LastName>
                    <ForeName>Michael</ForeName>
                </Author>
                <Author>
                    <LastName>Groettrup</LastName>
                    <ForeName>Marcus</ForeName>
                </Author>
            </Authors>
            <Affiliations>Division of Immunology, Department of Biology, University of Constance, Konstanz, Germany.</Affiliations>
            <ArticleChemicalList>Antigens, Viral;Autoantigens;Epitopes, T-Lymphocyte;Glycoproteins;Immunodominant Epitopes;Ki antigen;Multienzyme Complexes;Muscle Proteins;Peptide Fragments;Protein Subunits;Proteins;Receptors, Antigen, T-Cell, alpha-beta;Viral Proteins;glycoprotein peptide 33-41, Lymphocytic choriomeningitis virus;LMP-2 protein;Interferon-gamma;Cysteine Endopeptidases;LMP7 protein;Proteasome Endopeptidase Complex;Psmb10 protein, mouse</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Antigen Presentation(genetics; immunology); Antigens, Viral(immunology; metabolism); Autoantigens; Cell Line; Cell Line, Tumor; Cysteine Endopeptidases(deficiency; genetics; physiology); Cytotoxicity, Immunologic(genetics); Down-Regulation(genetics; immunology); Epitopes, T-Lymphocyte(immunology; metabolism); Glycoproteins(immunology; metabolism); Hydrolysis; Immunodominant Epitopes(immunology; metabolism); Interferon-gamma(physiology); Lymphocyte Activation(genetics); Lymphocytic Choriomeningitis(enzymology; genetics; immunology); Lymphocytic choriomeningitis virus(immunology); Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Molecular Sequence Data; Multienzyme Complexes(deficiency; genetics; physiology); Muscle Proteins(physiology); Peptide Fragments(immunology; metabolism); Proteasome Endopeptidase Complex; Protein Subunits(deficiency; genetics; physiology); Proteins(physiology); Receptors, Antigen, T-Cell, alpha-beta(immunology); T-Lymphocytes, Cytotoxic(enzymology; immunology; virology); Viral Proteins(immunology; metabolism)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>173</Volume>
                <Issue>6</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>gp 33-41</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KAVYNFATC</LinearSequence>
                        <StartingPosition>33</StartingPosition>
                        <EndingPosition>41</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11623</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>30001</EpitopeId>
                <ReferenceStartingPosition>33</ReferenceStartingPosition>
                <ReferenceEndingPosition>41</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Glycoprotein precursor  [Contains: Glycoprotein G1; Glycoprotein G2].</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1B</LocationOfData>
                        <TCellId>16294</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>KAVYNFATC</LinearSequence>
                                            <StartingPosition>33</StartingPosition>
                                            <EndingPosition>41</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Mice were immunized i.v. with LCMV, and spleens were taken after 1 month. Hybridoma Hyb33 is specific for gp-33-41/H-2K&lt;sup&gt;b&lt;/sup&gt;.  Spleen cells from LCMV immunized mice were stimulated with epitope peptide in vitro prior to hybridoma fusion.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10000067</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Glycoprotein polyprotein</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>11623</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>187</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Results show that IFN-γ enhanced presentation of gp33 by rVV-gp33 transfected MC57 fibroblasts.  Further studies suggest that this effect is due to the IFN-γ inducible subunits LMP2/LMP7 of the immunoproteasome.  Target cells were treated with or without IFN-γ for 3-days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1A</LocationOfData>
                        <TCellId>6282</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>KAVYNFATC</LinearSequence>
                                            <StartingPosition>33</StartingPosition>
                                            <EndingPosition>41</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Mice were immunized i.v. with LCMV, and spleens were taken after 1 month. Hybridoma Hyb33 is specific gp-33-41/H-2K&lt;sup&gt;b&lt;/sup&gt;.  Spleen cells were stimulated with epitope peptide in vitro prior to hybridoma fusion.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10000067</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Lymphocytic choriomeningitis virus</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11623</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>187</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Results show that IFN-γ enhanced presentation of gp33.  Further studies suggest that this effect is due to the IFN-γ inducible subunits LMP2/LMP7 of the immunoproteasome.  Target cells were treated with or without IFN-γ for 3-days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>gp 276-286</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SGVENPGGYCL</LinearSequence>
                        <StartingPosition>276</StartingPosition>
                        <EndingPosition>286</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P09991.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11623</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>58282</EpitopeId>
                <ReferenceStartingPosition>276</ReferenceStartingPosition>
                <ReferenceEndingPosition>286</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Glycoprotein precursor  [Contains: Glycoprotein G1; Glycoprotein G2].</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1B</LocationOfData>
                        <TCellId>16369</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SGVENPGGYCL</LinearSequence>
                                            <StartingPosition>276</StartingPosition>
                                            <EndingPosition>286</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Mice were immunized i.v. with LCMV, and spleens were taken after 1 month to make hybridomas. Hybridoma Hyb276 is specific gp-276-286/H-2D&lt;sup&gt;b&lt;/sup&gt;.  Spleen cells from infected mice were stimulated with peptide in vitro prior to hybridoma fusion.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10000067</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Glycoprotein polyprotein precursor</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>P09991.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>11623</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>187</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Results show that IFN-γ reduced presentation of gp276-286 by rVV-gp276 transfected MC57 fibroblasts.  Further studies suggest that this effect is due to the IFN-γ inducible subunits LMP2/LMP7 of the immunoproteasome.  Target cells were treated with or without IFN-γ for 3-days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1A</LocationOfData>
                        <TCellId>6317</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Lymphocytic choriomeningitis virus</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SGVENPGGYCL</LinearSequence>
                                            <StartingPosition>276</StartingPosition>
                                            <EndingPosition>286</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P09991.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Mice were immunized i.v. with LCMV, and spleens were taken after 1 month to make hybridomas. Hybridoma Hyb276 is specific gp-276-286/H-2D&lt;sup&gt;b&lt;/sup&gt;.  Spleen cells from LCMV immunized mice were stimulated with epitope peptide in vitro prior to hybridoma fusion.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone (Hybridoma)</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10090</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Lymphocytic choriomeningitis virus</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>11623</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>187</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Results show that IFN-γ reduced presentation of naturally processed gp276.  Further studies suggest that this effect is due to the IFN-γ inducible subunits LMP2/LMP7 of the immunoproteasome.  Target cells were treated with or without IFN-γ for 3-days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

